{"id":11202,"date":"2020-11-12T09:56:21","date_gmt":"2020-11-12T04:26:21","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11202"},"modified":"2025-05-06T13:06:54","modified_gmt":"2025-05-06T07:36:54","slug":"recent-pharma-happenings-for-egenesis-duke-decibel-genscript","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-egenesis-duke-decibel-genscript","title":{"rendered":"FDA authorizes first diagnostic test for Covid-19 antibodies; EGenesis&#8217;s collaboration with Duke;  Pancreatic Cancer research updates; Decibel scores $ 82 M"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a040ca4522de\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a040ca4522de\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-egenesis-duke-decibel-genscript\/#FDA_authorizes_first_diagnostic_test_for_COVID-19_antibodies_that_obstruct_the_virus_from_entering_cells\" >FDA authorizes first diagnostic test for COVID-19 antibodies that obstruct the virus from entering cells<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-egenesis-duke-decibel-genscript\/#EGenesis_collabs_with_Duke_to_help_develop_insulin-producing_pancreas_cell_xenotransplants\" >EGenesis collabs with Duke to help develop insulin-producing pancreas cell xenotransplants<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-egenesis-duke-decibel-genscript\/#Combating_pancreatic_cancer_with_a_novel_immuno-oncology_drug_conjugate\" >Combating pancreatic cancer with a novel immuno-oncology drug conjugate<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-egenesis-duke-decibel-genscript\/#Decibel_scores_USD_82_Million_to_push_hearing_loss_gene_therapy_into_the_clinic\" >Decibel scores USD 82 Million to push hearing loss gene therapy into the clinic<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_authorizes_first_diagnostic_test_for_COVID-19_antibodies_that_obstruct_the_virus_from_entering_cells\"><\/span><strong>FDA authorizes first diagnostic test for COVID-19 antibodies that obstruct the virus from entering cells<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The FDA has authorized the first <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\">COVID-19 diagnostic<\/a><\/strong> test, which identifies whether a person has the specific antibodies known to hinder the coronavirus from entering and infecting human cells.<\/p>\n\n\n\n<p>These neutralizing antibodies are perceived as a strong biomarker of potential immunity against the disease as compared to other antibodies created by the body that has only been used as a sign of prior exposure to the virus.<\/p>\n\n\n\n<p>The commercial diagnostic kit developed by GenScript is designed to give a test result within one hour. However, it is still not known how long these neutralizing antibodies can last within the body, and how many are required to confer protection against the novel coronavirus.<\/p>\n\n\n\n<p>GenScript\u2019s assay, which is developed with Duke-National University of Singapore Medical School, mimics the neutralization process using safer materials. It connects recombinant protein fragments of the coronavirus\u2019 receptor binding domain, which the virus utilizes to open and penetrate human cells, with an enzyme derived from horseradish roots.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"EGenesis_collabs_with_Duke_to_help_develop_insulin-producing_pancreas_cell_xenotransplants\"><\/span><strong>EGenesis collabs with Duke to help develop insulin-producing pancreas cell xenotransplants<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>EGenesis has declared a research collaboration with Duke University\u2019s school of medicine to develop its xenotransplantation technology into a cell therapy for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-gastroparesis-market-size\">diabetes<\/a><\/strong>.<\/p>\n\n\n\n<p>The project will commence assessing insulin-producing pancreatic islet cells that derived from animals, which have been genetically engineered to be compatible with humans. This covers an in vivo study of the xenotransplants in primates to ascertain surgical approaches before progressing to full clinical trials in the future.<\/p>\n\n\n\n<p>Millions live with type 1 diabetes, but with the advancements in gene-editing technology, there is currently, the potential of developing and carefully transplanting human-compatible xeno-islet cells that could allow these patients to decrease or kill their requirement for glucose monitoring and insulin injections. The research will be conducted at Duke that will help determine whether a minimally-invasive approach into human clinical studies might be possible or not, announced by Allan Kirk, M.D., Ph.D., chair of the department of surgery and a professor of immunology at Duke.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Combating_pancreatic_cancer_with_a_novel_immuno-oncology_drug_conjugate\"><\/span><strong>Combating pancreatic cancer with a novel immuno-oncology drug conjugate<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The researchers at Boston Children\u2019s Hospital have engineered a combination treatment that is designed to home in on and penetrate<strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-cancer-market\"> pancreatic cancer<\/a><\/strong> cells, and they have potential results in mice that the approach may work.<\/p>\n\n\n\n<p>The Boston Children\u2019s team developed an antibody-drug conjugate (ADC), which binds to ICAM1, a molecule on pancreatic tumour cells, and delivers a cancer-killing compound. In mouse models of pancreatic cancer, two doses of the drug shrivelled tumors and averted metastasis; the researchers published in the journal Advanced Science.<\/p>\n\n\n\n<p>The researchers began by screening the surface of pancreatic tumour cells for proteins, which were sufficient enough to serve as good binding targets. When they discovered ICAM1, they did not lose a chance to choose it as their target. ICAM1 facilitates some immune responses, and they knew from their prior research that the protein is abundant in other cancers, including <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/melanoma-market\">melanoma <\/a><\/strong>and<strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/triple-negative-breast-cancer-tnbc-market\"> triple-negative breast cance<\/a><\/strong>r. An ICAM1-targeted treatment developed at Boston Children\u2019s was effective in mouse models of triple-negative breast cancer as they reported last year.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Decibel_scores_USD_82_Million_to_push_hearing_loss_gene_therapy_into_the_clinic\"><\/span><strong>Decibel scores USD 82 Million to push hearing loss gene therapy into the clinic<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Decibel Therapeutics is grabbing USD 82 million to propel its lead programs into and through the clinic, including gene therapy for children with congenital deafness and a program leftover from its early days designed to shield hearing in cancer patients undergoing chemotherapy.<\/p>\n\n\n\n<p>The company took a comprehensive approach to search for therapeutic opportunities, mainly for the treatment of different forms of hearing loss. It casts a wide net, including disorders where children are born deaf, or become deaf early in life, and hearing loss, which comes with ageing or with extremely loud noises.<\/p>\n\n\n\n<p>Decibel focused on the approaches that restore the function of hair cells in the inner ear that sense and translate sound towards the end of 2019. Laurence Reid, Ph.D., Decibel\u2019s acting CEO said that they are doing either by gene replacement, providing normal copies of genes inherited in a mutant form from a child\u2019s parent, which leads to hearing loss, and by gene therapy to drive particular cellular pathways, which could cause the regeneration of hair cells in the vestibule or the cochlea.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA authorizes first diagnostic test for COVID-19 antibodies that obstruct the virus from entering cells The FDA has authorized the first COVID-19 diagnostic test, which identifies whether a person has the specific antibodies known to hinder the coronavirus from entering and infecting human cells. These neutralizing antibodies are perceived as a strong biomarker of potential [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":11204,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[18739,18738,349,420,5789],"industry":[17225],"therapeutic_areas":[17231],"class_list":["post-11202","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-decibel","tag-egenesis","tag-latest-pharma-news","tag-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>EGenesis deal; Decibel raises $82 M; Covid-19 antibodies diagnostics<\/title>\n<meta name=\"description\" content=\"The FDA has authorized the first COVID-19 diagnostic test, which identifies the specific antibodies known to hinder the coronavirus..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-egenesis-duke-decibel-genscript\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EGenesis deal; Decibel raises $82 M; Covid-19 antibodies diagnostics\" \/>\n<meta property=\"og:description\" content=\"The FDA has authorized the first COVID-19 diagnostic test, which identifies the specific antibodies known to hinder the coronavirus..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-egenesis-duke-decibel-genscript\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-12T04:26:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-06T07:36:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/12092922\/recent-pharma-news-and-updates-for-egenesis-duke-decibel-genscript.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"EGenesis deal; Decibel raises $82 M; Covid-19 antibodies diagnostics","description":"The FDA has authorized the first COVID-19 diagnostic test, which identifies the specific antibodies known to hinder the coronavirus..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-egenesis-duke-decibel-genscript","og_locale":"en_US","og_type":"article","og_title":"EGenesis deal; Decibel raises $82 M; Covid-19 antibodies diagnostics","og_description":"The FDA has authorized the first COVID-19 diagnostic test, which identifies the specific antibodies known to hinder the coronavirus..","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-egenesis-duke-decibel-genscript","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-11-12T04:26:21+00:00","article_modified_time":"2025-05-06T07:36:54+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/12092922\/recent-pharma-news-and-updates-for-egenesis-duke-decibel-genscript.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-egenesis-duke-decibel-genscript","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-egenesis-duke-decibel-genscript","name":"EGenesis deal; Decibel raises $82 M; Covid-19 antibodies diagnostics","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-egenesis-duke-decibel-genscript#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-egenesis-duke-decibel-genscript#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/12092922\/recent-pharma-news-and-updates-for-egenesis-duke-decibel-genscript.png","datePublished":"2020-11-12T04:26:21+00:00","dateModified":"2025-05-06T07:36:54+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"The FDA has authorized the first COVID-19 diagnostic test, which identifies the specific antibodies known to hinder the coronavirus..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-egenesis-duke-decibel-genscript"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-egenesis-duke-decibel-genscript#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/12092922\/recent-pharma-news-and-updates-for-egenesis-duke-decibel-genscript.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/12092922\/recent-pharma-news-and-updates-for-egenesis-duke-decibel-genscript.png","width":772,"height":482,"caption":"recent-pharma-news-and-updates-for-egenesis-duke-decibel-genscript"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/12092922\/recent-pharma-news-and-updates-for-egenesis-duke-decibel-genscript-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Decibel<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">EGenesis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Decibel<\/span>","<span class=\"advgb-post-tax-term\">EGenesis<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Nov 12, 2020","modified":"Updated on May 6, 2025"},"absolute_dates_time":{"created":"Posted on Nov 12, 2020 9:56 am","modified":"Updated on May 6, 2025 1:06 pm"},"featured_img_caption":"recent-pharma-news-and-updates-for-egenesis-duke-decibel-genscript","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11202"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11202\/revisions"}],"predecessor-version":[{"id":31722,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11202\/revisions\/31722"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11204"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11202"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11202"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}